Amylyx Pharmaceuticals (AMLX) Return on Equity (2022 - 2025)
Historic Return on Equity for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to 0.6%.
- Amylyx Pharmaceuticals' Return on Equity rose 5400.0% to 0.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.6%, marking a year-over-year increase of 5400.0%. This contributed to the annual value of 1.01% for FY2024, which is 11300.0% down from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Return on Equity of 0.6% as of Q3 2025, which was up 5400.0% from 1.01% recorded in Q2 2025.
- Amylyx Pharmaceuticals' 5-year Return on Equity high stood at 0.12% for Q4 2023, and its period low was 2.7% during Q1 2022.
- In the last 4 years, Amylyx Pharmaceuticals' Return on Equity had a median value of 0.71% in 2022 and averaged 0.81%.
- As far as peak fluctuations go, Amylyx Pharmaceuticals' Return on Equity skyrocketed by 22700bps in 2023, and later crashed by -17800bps in 2024.
- Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Return on Equity stood at 0.82% in 2022, then soared by 114bps to 0.12% in 2023, then tumbled by -1550bps to 1.67% in 2024, then surged by 64bps to 0.6% in 2025.
- Its Return on Equity was 0.6% in Q3 2025, compared to 1.01% in Q2 2025 and 1.19% in Q1 2025.